What was Evommune, Inc.'s revenue in Q3 FY2025?

Evommune, Inc. reported total revenue of $10.0M in Q3 FY2025.

What was Evommune, Inc.'s net profit in Q3 FY2025?

Evommune, Inc. reported net profit of $-12.5M in Q3 FY2025, a net margin of -124.8%.

What were Evommune, Inc.'s margins in Q3 FY2025?

Evommune, Inc. had operating margin of -133.3% in Q3 FY2025.

What was Evommune, Inc.'s EPS in Q3 FY2025?

Evommune, Inc. reported diluted EPS of $-8.07 in Q3 FY2025.

Evommune, Inc.EVMNEarnings & Financial Report

NYSE · Health Care · Pharmaceutical Preparations

Deep Analysis

Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory and immunological diseases. Its pipeline includes novel candidates targeting unmet medical needs for conditions such as atopic dermatitis, psoriasis, and other immune-mediated disorders, primarily serving global healthcare markets.

Q3 2025

Revenue

$10.0M

Gross Profit

N/A

Operating Profit

$-13.3M

Net Profit

$-12.5M

Gross Margin

N/A

Operating Margin

-133.3%

Net Margin

-124.8%

YoY Growth

N/A

EPS

$-8.07

Evommune, Inc. Q3 FY2025 Financial Summary

Evommune, Inc. reported revenue of $10.0M for Q3 FY2025, with a net profit of $-12.5M (-124.8% margin).

Key Financial Metrics

Total Revenue	$10.0M
Net Profit	$-12.5M
Gross Margin	N/A
Operating Margin	-133.3%
Report Period	Q3 FY2025

Income Statement

	Q3 2025
Revenue	$10.0M
YoY Growth	N/A

Balance Sheet

	Q3 2025
Assets	$84.5M
Liabilities	$10.7M
Equity	$-183.1M

Cash Flow

	Q3 2025
Operating CF	$-59.7M